Boston Scientific (BSX) PT Raised to $86 at Truist Securities
Truist Securities analyst Richard Newitter raised the price target on Boston Scientific (NYSE: BSX) to $86.00 (from $79.00) while maintaining a Buy rating.
The analyst commented: "Our estimates & PT continue to move higher following another excellent print marked by 13.1%/20% org. rev/EPS growth & a solid guidance raise. This result came in ahead of even elevated investor expectations and early US Farapulse results are setting up BSX to have one of the cleanest beat & raise profiles in lgcp MedTech. The 8-10% rev LRP (which some called aggressive when 1st issued) now looks conservative w/ 10-12% already on tap in '24. We see a clear path to accelerating DD rev & EPS growth, and BSX remains a preferred lgcp for us w/ a steady new product cadence, robust pipeline & attractive end-mkts."